Login to Your Account



Tardive dyskinesia drug shows promise in Phase II

By Catherine Shaffer
Staff Writer

Tuesday, January 7, 2014
Neurocrine Biosciences Inc.’s tardive dyskinesia candidate, NBI-98854, nailed its endpoints in a Phase IIb (Kinect 2) study by causing a significant change from baseline in the abnormal involuntary movement scale (AIMS) after six weeks of treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription